Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Inhibiting Lactate Production Halts Tumor Growth

April 11, 2014 11:00 am | News | Comments

A research team has found that targeting the enzyme responsible for the final step of glucose metabolism not only halts tumor growth in non-small-cell lung cancer, but also leads to the regression of established tumors. Read more...       

TOPICS:

Yeast Provides Genetic Clues to Drug Response

April 11, 2014 10:45 am | News | Comments

Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Read more...   

TOPICS:

AbbVie's Hep C Regimen Posts Promising Phase 3 Results

April 11, 2014 10:36 am | News | Comments

AbbVie announced that in two Phase 3 studies, adult, non-cirrhotic patients with chronic genotype 1 hepatitis C virus infection receiving the investigational regimen with ribavirin (RBV) for 12 weeks achieved sustained virologic response rates 12 weeks post-treatment of about 96%. Read more...

TOPICS:
Advertisement

Judge Enforces Generic Frova Settlement in Favor of Mylan

April 11, 2014 10:12 am | News | Comments

Mylan Inc. confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan, settling patent litigation in connection with Mylan's generic version of Frova. Read more...   

TOPICS:

Sovaldi Continues to Excel in Trials with Hep C, Advanced Liver Disease

April 11, 2014 10:01 am | News | Comments

Gilead Sciences Inc. announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi was administered for the treatment of chronic hepatitis C virus infection in patients with advanced liver disease. Read more...

TOPICS:

Governor Backs Medical Marijuana Trials

April 11, 2014 9:41 am | by Kathleen Foody | News | Comments

Georgia Gov. Nathan Deal on Thursday announced two separate efforts to pursue clinical trials on a cannabis-based drug that has shown promise in helping children who suffer from seizure disorders. Read more...           

TOPICS:

Promising Agents Burst Through 'Superbug' Defenses

April 10, 2014 3:26 pm | News | Comments

In the fight against "superbugs," scientists have discovered a class of agents called metallopolymers that can make some of the most notorious strains vulnerable to the same antibiotics that they once handily shrugged off. Read more...    

TOPICS:

Affimed’s Lymphoma Drug Shows Favorable Safety Profile, Activity

April 10, 2014 3:15 pm | News | Comments

Affimed Therapeutics AG announced further results from its Phase 1 clinical trial of AFM13 (a bispecific T and Ab antibody) as monotherapy for the treatment of patients with advanced relapsing/refractory (R/R) Hodgkin lymphoma. Read more... 

TOPICS:
Advertisement

Lung Fibrosis and Survival Improved in Preclinical Study of Genkyotex’s GKT137831

April 10, 2014 3:03 pm | News | Comments

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis. Read more...

TOPICS:

BMS Study Shows Potential for New Hep C Treatment

April 10, 2014 2:57 pm | News | Comments

Bristol-Myers Squibb Co. announced Phase 3 results from a global study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir and asunaprevir among genotype 1b hepatitis C virus (HCV) infected patients. Read more...   

TOPICS:

Tocagen Reports Positive Trial Results for Brain Cancer Combo

April 10, 2014 2:50 pm | News | Comments

Tocagen Inc. announced updated interim clinical data from two ongoing investigational studies of Toca 511 in combination with Toca FC in 68 patients with recurrent high grade glioma. Read more...                

TOPICS:

Merck’s Hep C Drug Moving to Phase 3

April 10, 2014 2:34 pm | News | Comments

Merck announced additional data from the C-WORTHy study, a Phase 2 trial evaluating a regimen combining MK-5172, an investigational hepatitis C virus NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection. Read more...

TOPICS:

Breaking News: Drug Ups Survival in H1N1 Mice

April 10, 2014 12:00 pm | News | Comments

A new study reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus, a finding that paves the way for an urgently needed therapy. Read more...

TOPICS:

Ampio, Paladin Labs Partner on Zertane Rights

April 10, 2014 10:55 am | News | Comments

Ampio Pharmaceuticals Inc. announced that its subsidiary Vyrix Pharmaceuticals has signed an agreement with Paladin Labs Inc. to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America. Read more...

TOPICS:

Gilead Posts Positive Results for All-Oral Sofosbuvir Regimens

April 10, 2014 10:47 am | News | Comments

Gilead Sciences Inc. announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading